Key Takeaways
- Stellar quarter, confident outlook: Q4 capped a year that overachieved operating profit targets, and management expects the performance trajectory to keep improving, targeting low double-digit revenue growth and a ~20% EBITDA margin for FY26.
- France GMP unlocks the next leg: The GMP certificate makes both filling lines fully operational, with development orders already in hand and commercial production expected over the next 1–2 years, a key step toward turning around the loss-making French entity.
- India CRAMS is the turnaround story: Full-year revenue grew 35% to INR 290 crores, and management sees a path to INR 800 crores in peak revenue from India assets within 2–3 years as upgraded sites ramp up.
- A Japanese innovator is co-investing >CHF 2.5 crore: The client is funding infrastructure for a complex ADC drug linker molecule in Switzerland, a trust-based deal that validates Carbogen's quality and could represent 10% of Carbogen's revenue.
- What to watch next quarter: Whether the India CRAMS turnaround sustains its momentum, the pace of new order intake from the India-Carbogen collaboration, and any early signs of commercial production traction in France.
France: The GMP Catalyst
- The milestone: The GMP certificate from French authorities is the foundational permit for commercial production, making both filling lines fully qualified: one with a lyophilizer for solid forms, one for high-potent API solutions.
- Early traction: Development orders under GMP conditions have already been received, and management expects increased market interest to convert into commercial production over the next 1–2 years.
- Financial drag today: The French entity is currently loss-making, which elevates the consolidated effective tax rate; as it turns around and generates profit, the tax rate should come down.
- Revenue doubling planned: Based on the current business plan, French entity revenue is expected to double in FY26 from its EUR 8.6 million base.
- Breakeven path: Management is aiming to break even at the operating level, with the worst-case breakeven point pegged at EUR 15–16 million in revenue.
Stephan Fritschi: "the GMP certificate is the basis and the fundament to successfully work on GMP products and GMP commercial production"
India CRAMS Turnaround
- The numbers: India CRAMS delivered INR 80 crores in Q4 revenue and INR 290 crores for the full year, representing 35% growth and what management called the "start of a turnaround."
- The asset base: Bavla and Naroda sites have undergone major CAPEX and operational efficiency upgrades; with all units running, total revenue potential from India assets is pegged at INR 800 crores, achievable in the next 2–3 years.
- Bavla run-rate target: The Bavla site has historically done INR 100–120 crores per quarter; management is targeting that INR 100 crores quarterly number in FY26, with Q4 typically the strongest quarter.
- Margin recovery path: India CRAMS historically achieved 35–40% EBITDA margins; the cost base has increased due to upgrades, but margins should move toward 20–25% as revenues increase.
- Synergy with Carbogen: New leadership is driving collaboration: Carbogen is limited on reactor capacity while Dishman India is suited for fast process development; joint procurement is being explored, and life cycle management will see Carbogen transfer mature molecules to Dishman and Bavla for more cost-effective production.
Harshil Dalal: "If you see historically we have done upwards of 35%, 40% EBITDA margins for that particular business. So as the revenues keep on increasing, obviously, the cost base has increased because of the improvements that we have done, but we do expect that the margin should move towards the 20%, 25% mark."
Carbogen Amcis: Development Strength & Client Trust
- Q4 revenue mix: Carbogen's Q4 was dominated by development revenue, unlike other quarters where commercial revenue leads; the segment still delivered a very strong EBITDA margin of approximately 25% in Q4.
- Japanese co-investment: A Japanese innovator is co-investing over CHF 2.5 crore in Switzerland for an ADC drug linker complex molecule; the client pays for infrastructure, and Dishman delivers product at an agreed price until the investment amount is reached, with the co-investment split at roughly 50%.
- Revenue potential: The ADC plant project could represent 10% of Carbogen's entire revenue, though there is flexibility depending on market outlook and the client's commercial success.
- Phase III pipeline normalizes: Late-phase projects moved from 16 to 14; one or two dropped off because the client made a recalculation, which management characterized as normal business variability.
- Why clients co-invest: The chemistry in the Japanese client's case is very complex and challenging; Carbogen's success in validation built the trust that led the client to commit to a long-term, co-invested relationship.
Stephan Fritschi: "Quality, reliability and how we approach our customers and projects. So these are key words what are important to our clients. When we start to work with the client, we establish a relationship with them, which is based on trust. And clients get confident that we succeed."
Cholesterol, Vitamin D & Netherlands
- Strong Q4: Revenue from cholesterol and vitamin D analogues was higher in Q4 than the quarterly run rate of the first three quarters, and the Dutch subsidiary overachieved its budget for the full year.
- Raw material tailwind: Key raw material prices increased substantially in FY25 but have been lowered significantly starting the current financial year; management successfully negotiated lower wool grease prices, which should drive higher profitability.
- Margin target: Cholesterol and vitamin D analogue margins are targeted at 15–20%, with improvement expected to start showing from the current financial year due to the lower raw material costs.
- Revenue mix: Cholesterol contributed approximately 60% and vitamin D analogues 40% of the Dutch business in both Q4 and the full year.
Margins, Costs & Balance Sheet
- Q4 EBITDA margin: 21.4%, which management said is "very much in line with what we would want to achieve for the full year in the next financial year."
- FY26 margin target: Company-level EBITDA margin should be closer to the 20% mark, with an EBITDA target of INR 550–570 crores at a minimum, and potentially higher.
- Employee cost pressure: Employee cost as a percentage of sales increased partly due to Swiss franc appreciation (~5% YoY), since most employee costs are in Swiss francs while revenues are mostly in USD; absolute employee cost is unlikely to decline because over 50% of staff are PhDs tied to development work.
- Finance cost relief: Finance costs are expected to decrease 10–15% in FY26 as financial covenants with banks improve and net debt keeps declining by INR 100–200 crores annually.
- CAPEX moderating: FY26 CAPEX is planned at EUR 25–30 million (~INR 250–300 crores), and future CAPEX will require proper business cases with customer commitment or co-investment agreements assuring future revenue.
- ROCE path: ROCE is currently low (~2%) due to significant CAPEX over the last 2–3 years; management expects double-digit ROCE in 3 years as the French entity generates profits, India ramps up, Netherlands margins improve, and Switzerland continues performing.
- Inventory explained: High inventory days (analyst-cited 550–650 days) are largely driven by commercial manufacturing projects where customers mandate keeping certain inventory levels, including finished goods or WIP for product launches.
Harshil Dalal: "It was one of the best quarters for us, and this is the third consecutive quarter where I have been saying this. So we just expect the performance to keep on improving from here on in the same manner as the last 3 quarters have been."
New Geographies & Capabilities
- China: The Shanghai site received a drug manufacturing license after a Chinese FDA inspection in January 2025, enabling future GMP production for the Chinese market; management is focused on gaining more projects out of China.
- Swiss expansion: The Japanese client's co-investment will expand capacity with bigger reactors and new capabilities in Switzerland, expected to be operational in 2027.
- India-Carbogen collaboration: Drug substance sales managers from Carbogen visited Dishman India to learn about capabilities, generating client interest in additional services from the Indian parent; new orders from this collaboration are expected in the coming weeks.
- CRAMS market focus: Management sees strong interest and investment in CRAMS outside the U.S., with challenges in the U.S. market; the company is focusing on non-U.S. markets and looking into alliances and product expansion projects in Europe and India.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Low double-digit growth targeted; 12–15% CAGR over medium term | FY26 / 3–5 years |
| EBITDA | INR 550–570 crores minimum, ~20% margin; INR 750 crores medium-term | FY26 / 2–3 years |
| Finance cost reduction | 10–15% lower vs FY25 | FY26 |
| Net debt reduction | Decline by INR 100–200 crores annually | Ongoing |
| French entity revenue | Double from EUR 8.6 million base | FY26 |
| French entity breakeven | Operating breakeven targeted; worst case at EUR 15–16 million revenue | Not specified |
| India assets peak revenue | INR 800 crores with all units running | 2–3 years |
| Bavla quarterly run-rate | INR 100 crores per quarter | FY26 |
| ROCE | Double-digit | 3 years |
| CAPEX | EUR 25–30 million (~INR 250–300 crores) | FY26 |
| Swiss expansion operational | Bigger reactors and new capabilities for Japanese client | 2027 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations | ₹2,711 cr for full FY25, +3.7% YoY; Q4 grew 9.4% YoY |
| EBITDA | ₹153 cr in Q4, vs ₹63.4 cr in Q4 FY24; full FY25 ₹472 cr vs reported ₹296 cr in FY24 |
| EBITDA margin | 21.4% in Q4; full FY25 17.4% |
| Profit before tax | ₹27.7 cr in Q4; full FY25 ₹19.3 cr |
| Finance cost | ₹42 cr in Q4, down from ₹48 cr in previous quarter; expected 10–15% lower in FY26 |
| Net debt | ₹157 cr as of Mar 31, 2025, down from ₹163 cr as of Mar 31, 2024 |
| Carbogen Amcis CRAMS revenue | ₹489 cr in Q4, +9% YoY; full FY25 ₹2,003 cr vs ₹1,953 cr in FY24 |
| Carbogen Amcis CRAMS EBITDA margin | ~25% in Q4 vs 15.6% in Q4 FY24; full FY25 19.7% |
| Cholesterol and Vitamin D analogues revenue | ₹121 cr in Q4 vs ₹91 cr in Q4 FY24; full FY25 ₹305 cr |
| Cholesterol and Vitamin D analogues EBITDA margin | 10.3% for full FY25 vs 17.8% in FY24 |
| India CRAMS revenue | ₹80 cr in Q4; full FY25 ₹290 cr, +35% YoY |
| India CRAMS EBITDA margin | 17.3% in Q4 vs 5.2% in Q4 FY24; full FY25 13% |
| Quats and Generics revenue | ₹113 cr for full FY25, flattish vs ₹115 cr in FY24 |
| French entity revenue | €8.6 mn for full FY25; expected to double in FY26 |
| French entity EBITDA loss | €6.5 mn for full FY25 |
| FY26 EBITDA target | ₹550–570 cr, targeting ~20% margin |
| Revenue CAGR expectation | 12–15% over next 3–5 years |
| India assets peak revenue potential | ~₹800 cr with all units running |
| Phase III late-stage projects | 14, down from 16 during the year |
| FY26 CAPEX guidance | ₹250–300 cr (€25–30 mn), including ~₹170–180 cr maintenance CAPEX |